CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Short Interest Down 83.3% in August

Key Points

• CSL Limited's short interest decreased by 83.3% in August, dropping from 7,800 shares to just 1,300 shares as of August 31st.
• The company's stock traded down 1.5% to $68.43 on Thursday, with a total trading volume of 257,954 shares.
• CSL Limited operates through segments such as CSL Behring and CSL Seqirus, focusing on biopharmaceuticals and vaccines across multiple countries.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - ) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totaling 1,300 shares, a decrease of 83.3% from the August 15th total of 7,800 shares. Currently, 0.0% of the company's shares are short sold. Based on an average daily volume of 283,800 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 283,800 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company's shares are short sold.

CSL Trading Down 1.5%

OTCMKTS CSLLY traded down $1.05 during trading on Thursday, reaching $68.43. 257,954 shares of the company's stock traded hands, compared to its average volume of 91,535. CSL has a 12-month low of $65.13 and a 12-month high of $105.66. The company has a current ratio of 1.86, a quick ratio of 0.85 and a debt-to-equity ratio of 0.45. The company's 50 day simple moving average is $79.62 and its two-hundred day simple moving average is $79.09.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.